The Life Sciences industry has been on alert for several years now and there is little reason to believe that the USDOJ and SEC will shift their enforcement focus away from this highly complex industry encompassing pharmaceutical companies, medical device outfits, biotech entities and CROs. In addition to the FCPA, non-US anti-corruption legislation is increasingly on the minds of the industry’s global players as it not only increases local enforcement but also spurs cross-border cooperation between US and non-US enforcement agencies. The Forum will delve into the most pressing contemporary concerns faced by the industry, offer best-practice benchmarking and detailed debate as well as expert analyses on regulators’ enforcement priorities.
For more information, CLICK HERE
ACI is devoted to providing the business intelligence that senior decision-makers need to respond to challenges in the US and around the world. ACI conferences offer a combination of lectures, hands-on workshops, panels, roundtables and case studies to ensure that the right information is delivered in the right format.
|Event End Date||2018/06/19|
|Location||Park Lane Hotel|